Concert Pharmaceuticals Inc. (NASDAQ:CNCE) fell 3.5% during trading on Thursday . The stock traded as low as $11.25 and last traded at $11.32, with a volume of 54,870 shares. The stock had previously closed at $11.73.

Several brokerages recently commented on CNCE. Brean Capital reissued a “buy” rating on shares of Concert Pharmaceuticals in a report on Saturday, April 30th. Zacks Investment Research lowered shares of Concert Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday. Finally, Stifel Nicolaus assumed coverage on shares of Concert Pharmaceuticals in a research report on Friday, July 1st. They issued a “buy” rating and a $23.00 price target on the stock. Two research analysts have rated the stock with a sell rating and six have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $26.43.

The stock has a market cap of $248.82 million and a PE ratio of 13.45. The firm has a 50-day moving average of $11.99 and a 200-day moving average of $13.59.

Concert Pharmaceuticals (NASDAQ:CNCE) last posted its earnings results on Thursday, May 5th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by $0.18. On average, equities analysts anticipate that Concert Pharmaceuticals Inc. will post ($2.16) earnings per share for the current year.

In related news, CEO Roger D. Tung bought 19,610 shares of the business’s stock in a transaction dated Wednesday, May 11th. The stock was bought at an average price of $10.55 per share, for a total transaction of $206,885.50. Following the purchase, the chief executive officer now owns 538,965 shares in the company, valued at approximately $5,686,080.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

An institutional investor recently raised its position in Concert Pharmaceuticals stock. Dimensional Fund Advisors LP increased its position in Concert Pharmaceuticals Inc. (NASDAQ:CNCE) by 405.9% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 224,348 shares of the company’s stock after buying an additional 179,998 shares during the period. Dimensional Fund Advisors LP owned 1.02% of Concert Pharmaceuticals worth $4,256,000 at the end of the most recent quarter.

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others segment. It has clinical candidates under development, including AVP-786, CTP-656, CTP-730 and JZP-386.